Published in AIDS on March 29, 2002
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child (2012) 1.73
Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis (2003) 1.39
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem (2004) 1.35
HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes (2003) 1.25
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Antiretroviral therapy exposure and insulin resistance in the Women's Interagency HIV study. J Acquir Immune Defic Syndr (2008) 1.22
Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis (2006) 1.15
Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One (2012) 1.08
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS (2007) 1.07
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr (2005) 1.07
HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep (2008) 1.06
Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection. Am J Infect Dis (2006) 1.04
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol (2009) 1.01
Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine (2011) 0.96
Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest (2002) 0.96
Antiretroviral therapy in the clinic. J Virol (2010) 0.95
Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95
Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia. HIV Clin Trials (2011) 0.94
Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med (2008) 0.93
The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism. Curr Infect Dis Rep (2004) 0.90
Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol (2008) 0.89
Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis (2006) 0.87
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
Potential of Spirulina Platensis as a Nutritional Supplement in Malnourished HIV-Infected Adults in Sub-Saharan Africa: A Randomised, Single-Blind Study. Nutr Metab Insights (2011) 0.86
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS (2008) 0.84
Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.82
HIV infection and glycemic response to newly initiated diabetic medical therapy. AIDS (2012) 0.81
Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord (2007) 0.79
Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab (2008) 0.79
Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infect Dis (2012) 0.78
Hormonal contraception and HIV-positive women: metabolic concerns and management strategies. J Midwifery Womens Health (2008) 0.78
Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr (2010) 0.77
Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. Afr Health Sci (2013) 0.76
The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men. J Acquir Immune Defic Syndr (2009) 0.75
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clin Trials (2016) 0.75
Development of GLUT4-selective antagonists for multiple myeloma therapy. Eur J Med Chem (2017) 0.75
Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 27.52
Obesity and insulin resistance. J Clin Invest (2000) 10.47
Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med (1990) 7.13
Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature (2001) 6.70
Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. N Engl J Med (1999) 5.05
HIV-protease inhibitors. N Engl J Med (1998) 4.42
The theoretical bases of indirect calorimetry: a review. Metabolism (1988) 4.12
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr (2000) 3.11
Signaling mechanisms that regulate glucose transport. J Biol Chem (1999) 2.75
The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem (2000) 2.55
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS (1999) 2.54
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS (1999) 2.47
Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J Biol Chem (1999) 2.33
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS (1998) 2.05
Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS (2001) 1.90
Indinavir concentrations and antiviral effect. Pharmacotherapy (1999) 1.82
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes (2001) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother (1998) 1.46
The insulin-sensitive glucose transporter. Int Rev Cytol (1992) 1.26
Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.24
Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol (1998) 1.16
The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes (2001) 1.14
Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr (2001) 1.11
The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia (2000) 0.95
The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes (2001) 0.93
An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. J Pharm Biomed Anal (2001) 0.90
Dietary regulation of glucose transporter gene expression: tissue specific effects in adipose cells and muscle. J Nutr (1994) 0.88
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Self-management interventions for chronic illness. Lancet (2004) 5.33
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res (2004) 4.67
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr (2005) 4.02
Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol (2005) 3.96
Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA (2006) 3.20
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation (2010) 2.71
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol (2005) 2.56
The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol (2010) 2.50
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol (2006) 2.44
Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes (2005) 2.43
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS (2009) 2.29
Microalbuminuria in HIV infection. AIDS (2007) 2.28
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Duration of lactation is associated with lower prevalence of the metabolic syndrome in midlife--SWAN, the study of women's health across the nation. Am J Obstet Gynecol (2008) 2.15
Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr (2008) 2.05
Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med (2003) 2.02
Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring) (2006) 2.00
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr (2003) 1.95
Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med (2007) 1.94
The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr (2008) 1.94
Lactation intensity and postpartum maternal glucose tolerance and insulin resistance in women with recent GDM: the SWIFT cohort. Diabetes Care (2011) 1.93
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr (2009) 1.83
Ten nights of moderate hypoxia improves insulin sensitivity in obese humans. Diabetes Care (2013) 1.75
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone (2012) 1.72
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation. Menopause (2012) 1.66
Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ (2006) 1.66
The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis (2005) 1.64
The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS (2004) 1.64
Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus: A Prospective Cohort Study. Ann Intern Med (2015) 1.64
Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr (2008) 1.63
Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis (2008) 1.63
Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism (2007) 1.60
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics (2003) 1.57
Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg (2009) 1.56
Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet (2008) 1.54
Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51
Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab (2006) 1.49
Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis (2011) 1.48
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
Time- and exercise-dependent gene regulation in human skeletal muscle. Genome Biol (2003) 1.44
Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab (2004) 1.44
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr (2005) 1.42
Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res (2004) 1.40
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.39
Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (2008) 1.38
Repression of farnesoid X receptor during the acute phase response. J Biol Chem (2003) 1.36
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS (2010) 1.35
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34
HIV viremia and changes in kidney function. AIDS (2009) 1.32
LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res (2008) 1.30
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg (2009) 1.28
Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg (2010) 1.27
Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis (2003) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J Lipid Res (2003) 1.27
Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis (2012) 1.26
Factors associated with weight loss after gastric bypass. Arch Surg (2008) 1.26
Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr (2007) 1.25
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (2008) 1.24
Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab (2007) 1.24
Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation (2008) 1.24
Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS (2002) 1.21
Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab (2002) 1.20
The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab (2009) 1.20